BACKGROUND & AIMS: The peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is a nuclear receptor that regulates expression of mediators of lipid metabolism and the inflammatory response. There is controversy over the pro-oncogenic or antioncogenic effects of PPARG, and little is known about its prognostic significance in colon cancer. METHODS: Among 470 patients with colorectal cancer (stages I-IV) identified in 2 independent prospective cohorts, PPARG expression was detected in 102 tumors (22%) by immunohistochemistry. Cox proportional hazards models were used to compute hazard ratios (HRs) of colorectal cancer-specific and overall mortalities, adjusted for patient characteristics and molecular features including cyclooxygenase 2, fatty acid synthase, KRAS, BRAF, PIK3CA, p53, p21, beta-catenin, LINE-1 hypomethylation, microsatellite instability (MSI), and the CpG island methylation phenotype (CIMP). RESULTS: Compared with patients with PPARG-negative tumors, patients with PPARG-positive tumors had significantly lower overall mortality, determined by Kaplan-Meier analysis (P=.0047), univariate Cox regression (HR, 0.55; 95% confidence interval [CI], 0.37-0.84; P=.0053), and multivariate analysis (adjusted HR, 0.43; 95% CI, 0.27-0.69; P=.0004). Patients with PPARG-positive tumors experienced lower colorectal cancer-specific mortality (adjusted HR, 0.44; 95% CI, 0.25-0.79; P=.0054). The relationship between PPARG and lower mortality did not appear to be significantly modified by MSI, CIMP, LINE-1, or the other clinical and molecular variables examined (all P(interaction)>.05). CONCLUSIONS: Tumor expression of PPARG is independently associated with longer survival of patients. PPARG expression appears to mark an indolent subset of colorectal cancers.
BACKGROUND & AIMS: The peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is a nuclear receptor that regulates expression of mediators of lipid metabolism and the inflammatory response. There is controversy over the pro-oncogenic or antioncogenic effects of PPARG, and little is known about its prognostic significance in colon cancer. METHODS: Among 470 patients with colorectal cancer (stages I-IV) identified in 2 independent prospective cohorts, PPARG expression was detected in 102 tumors (22%) by immunohistochemistry. Cox proportional hazards models were used to compute hazard ratios (HRs) of colorectal cancer-specific and overall mortalities, adjusted for patient characteristics and molecular features including cyclooxygenase 2, fatty acid synthase, KRAS, BRAF, PIK3CA, p53, p21, beta-catenin, LINE-1 hypomethylation, microsatellite instability (MSI), and the CpG island methylation phenotype (CIMP). RESULTS: Compared with patients with PPARG-negative tumors, patients with PPARG-positive tumors had significantly lower overall mortality, determined by Kaplan-Meier analysis (P=.0047), univariate Cox regression (HR, 0.55; 95% confidence interval [CI], 0.37-0.84; P=.0053), and multivariate analysis (adjusted HR, 0.43; 95% CI, 0.27-0.69; P=.0004). Patients with PPARG-positive tumors experienced lower colorectal cancer-specific mortality (adjusted HR, 0.44; 95% CI, 0.25-0.79; P=.0054). The relationship between PPARG and lower mortality did not appear to be significantly modified by MSI, CIMP, LINE-1, or the other clinical and molecular variables examined (all P(interaction)>.05). CONCLUSIONS: Tumor expression of PPARG is independently associated with longer survival of patients. PPARG expression appears to mark an indolent subset of colorectal cancers.
Authors: Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Kaori Shima; Natsumi Irahara; Shoko Kure; Andrew T Chan; Jeffrey A Engelman; Peter Kraft; Lewis C Cantley; Edward L Giovannucci; Charles S Fuchs Journal: J Clin Oncol Date: 2009-02-23 Impact factor: 44.544
Authors: C A Eads; K D Danenberg; K Kawakami; L B Saltz; C Blake; D Shibata; P V Danenberg; P W Laird Journal: Nucleic Acids Res Date: 2000-04-15 Impact factor: 16.971
Authors: A M Lefebvre; I Chen; P Desreumaux; J Najib; J C Fruchart; K Geboes; M Briggs; R Heyman; J Auwerx Journal: Nat Med Date: 1998-09 Impact factor: 53.440
Authors: Geoffrey D Girnun; Wendy M Smith; Stavit Drori; Pasha Sarraf; Elisabetta Mueller; Charis Eng; Prashant Nambiar; Daniel W Rosenberg; Roderick T Bronson; Winfried Edelmann; Raju Kucherlapati; Frank J Gonzalez; Bruce M Spiegelman Journal: Proc Natl Acad Sci U S A Date: 2002-10-07 Impact factor: 11.205
Authors: Ludovic Barault; Céline Charon-Barra; Valérie Jooste; Mathilde Funes de la Vega; Laurent Martin; Patrick Roignot; Patrick Rat; Anne-Marie Bouvier; Pierre Laurent-Puig; Jean Faivre; Caroline Chapusot; Francoise Piard Journal: Cancer Res Date: 2008-10-15 Impact factor: 12.701
Authors: Rangaswamy Govindarajan; Luke Ratnasinghe; Debra L Simmons; Eric R Siegel; Madhu V Midathada; Lawrence Kim; Peter J Kim; Randall J Owens; Nicholas P Lang Journal: J Clin Oncol Date: 2007-04-20 Impact factor: 44.544
Authors: Mart Dela Cruz; Ramesh K Wali; Laura K Bianchi; Andrew J Radosevich; Susan E Crawford; Lisa Jepeal; Michael J Goldberg; Jaclyn Weinstein; Navneet Momi; Priya Roy; Audrey H Calderwood; Vadim Backman; Hemant K Roy Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-08-25 Impact factor: 4.254
Authors: Tobias Gutting; Christian A Weber; Philip Weidner; Frank Herweck; Sarah Henn; Teresa Friedrich; Shuiping Yin; Julia Kzhyshkowska; Timo Gaiser; Klaus-Peter Janssen; Wolfgang Reindl; Matthias P A Ebert; Elke Burgermeister Journal: Oncoimmunology Date: 2018-02-01 Impact factor: 8.110
Authors: Nicholas P Evans; Sarah A Misyak; Eva M Schmelz; Amir J Guri; Raquel Hontecillas; Josep Bassaganya-Riera Journal: J Nutr Date: 2010-01-20 Impact factor: 4.798